Report
Oscar Haffen Lamm

Abivax: Takeaways from the KOL event

Abivax hosted a virtual KOL event yesterday with Dr. David T. Rubin featuring i) a discussion on the unmet medical need and current treatment landscape for patients with UC with a focus on obefazimod's MoA as a key differentiating factor, ii) a review of Obefazimod's phase 2b data as well as phase
Underlying
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Oscar Haffen Lamm

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch